GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

• Published in: Molecular metabolism (Germany) Vol. 46; p. 101102
• Main Authors: Nauck, Michael A., Quast, Daniel R., Wefers, Jakob, Meier, Juris J.
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.04.2021; Elsevier
• Subjects: Albiglutide; Body weight; Cardiovascular disease; Dulaglutide; Exenatide; Glucagon-like peptide-1 receptor agonists; Liraglutide; Lixisenatide; Review; Semaglutide; Type 2 diabetes; Type 2 diabetes; Dulaglutide; Body weight; Semaglutide; Cardiovascular disease; Glucagon-like peptide-1 receptor agonists; Albiglutide; Exenatide; Lixisenatide; Liraglutide

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals betw...